European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

Aquablation shows promise for treating enlarged prostates while preserving sexual function

Results from WATER III trial presented at EAU25 suggests that waterjet surgery may offer men relief from BPH symptoms without compromising ejaculatory function.

Wed, 26 Mar 2025
EAU 25AquablationBPE LUTSBPEBPO Management

New study results presented at EAU25 in Madrid highlighted the potential of aquablation - a high-pressure waterjet surgery - for treating men with large prostates affected by benign prostatic hyperplasia (BPH). The technique appears to deliver comparable urinary outcomes to standard laser surgery, with a significantly lower risk of retrograde ejaculation, a common side effect that can affect sexual satisfaction.

The findings come from the WATER III trial, led by Prof. Manuel Ritter of the University Hospital Bonn. The trial enrolled 202 men with large prostates (80–180 mL), comparing aquablation therapy with conventional laser surgeries such as Holmium laser enucleation (HoLEP) and Thulium laser enucleation (ThuLEP).

Aquablation vs. laser surgery: What the data shows

While short-term results for symptom relief were similar across both groups, the difference in sexual side effects was notable. Among sexually active participants, only 15% in the aquablation group experienced retrograde ejaculation, compared to 77% in the laser surgery group. Urinary incontinence was also less frequent with aquablation (9%) than with laser treatments (20%).

“These patients are very happy to get rid of their medication and symptoms,” said Prof. Ritter. “The fact that aquablation also preserves ejaculatory function offers clear advantages for those who wish to maintain their sex lives after surgery.”

Expert Insights from EAU25

Prof. Cosimo De Nunzio (IT) discussed the findings on EAUTV during EAU25: “Retrograde ejaculation is a major concern for many men undergoing BPH treatment. Aquablation presents a promising option, especially for those prioritising sexual function. However, we must acknowledge the short three-month follow-up and the need for further research into long-term outcomes and additional patient groups.”

Aquablation, which uses robotic assistance and real-time ultrasound imaging, has previously been shown to reduce sexual side effects in smaller prostates. The WATER III trial is the first to demonstrate its benefits for larger prostates, potentially expanding treatment access and shortening waiting times.

In this EAU25 edition of EAUTV, experts Prof. Cosimo De Nunzio, Dr. Manuela Tutolo, and Prof. Manuel Ritter explore the latest advances in treating overactive bladder (OAB) and benign prostatic obstruction (BPO), including insights from the WATER III trial on Aquablation for enlarged prostates.

More information

Read the press release here.
Watch the webcast of the presentation here.

Share this article

Suggested for you

See all
About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer